VANCOUVER, BC / ACCESS Newswire / August 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE) (OTCQB:LOBEF) (FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, announces the closing of the non-brokered private placement (the " Offering ") of up to 8,535,625 common share of the Company (each, a " Share ") at a price of $0.04 per Share for gross... Read More

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, is pleased to announce a non-brokered private placement (the " Offering ") of up to 8,535,625 common share of the Company (each, a " Share ") at a price of $0.04 per Share for... Read More

VANCOUVER, BC / ACCESS Newswire / July 29, 2025 / Lobe Sciences Ltd. (CSE:LOBE) (OTCQB:LOBEF) (FWB:LOBE.F), a biopharmaceutical company focused on developing therapeutics for rare and underserved diseases, today announced its formal engagement with ArcStone Securities and Investments Corp. ("ArcStone"), a capital markets advisory firm. Under the terms of the agreement, ArcStone will provide Lobe Sciences with comprehensive... Read More

VANCOUVER, BC / ACCESS Newswire / July 16, 2025 / Lobe Sciences Ltd. (CSE:LOBE) (OTCQB:LOBEF) (FWB:LOBE.F), a biopharmaceutical company committed to developing innovative treatments for underserved diseases, today announced that it has settled an outstanding debt of CAD$11,596.22 owed to Gibbsons P.C. for legal services previously provided to the Company. In satisfaction of this obligation, Lobe has issued 546,206 common... Read More

European Unitary Patent EP4117446 Validated - Lobe Sciences secures patent protection in 17 EU member states for its DHA and egg yolk-based composition designed to manage Sickle Cell Disease. Covers Altemia(R) Medical Food Formula - The patented composition underpins Altemia(R), a physician-supervised medical food formulated to address long-chain fatty acid deficiencies common in SCD patients. Supports Global Expansion... Read More

New subsidiary, Cynaptec Pharmaceuticals, established to hold global rights to Conjugated Psilocin™ $6 million investment in Cynaptec Pharmaceuticals secured to advance research and early-stage clinical trials for chronic cluster headaches and addiction Option for an additional $20 million investment in Cynaptec Pharmaceuticals to support Phase 3 clinical development VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / June 17,... Read More

Lobe Sciences Ltd. has appointed Mr. Yong Yao as Chief Financial Officer and Executive Vice President, effective June 1, 2025, to lead the company's financial strategy during its next phase of growth. Mr. Yao brings over 25 years of experience across finance and biotech, with executive roles at companies such as Mountain Valley MD and global firms like Scotiabank and Morgan Stanley. His appointment marks a strategic shift to... Read More

Private Placement of US$6 Million to fund additional pre-clinical research, Phase 1 and Phase 2a clinical studies US$20 Million additional option included in Private Placement to fund the Phase 3 clinical program in chronic cluster headache Lobe creates Cynaptec Pharmaceuticals, Inc. which will own and develop Conjugated Psilocin TM VANCOUVER, BC / ACCESS Newswire / April 14, 2025 / Lobe Sciences Ltd. ("Lobe Sciences" or the... Read More

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / April 4, 2025 / Lobe Sciences Ltd. ("Lobe" or the "Company") (CSE:LOBE) (OTCQB:LOBEF) (FWB:LOBE.F) , a commercial stage biopharmaceutical company focused on developing products using lipid technology to treat diseases with significant unmet medical needs is providing a corporate update with respect to certain recent transactions. The Company wishes to provide notice of the... Read More

U.S. Patent Office issues notice of allowance for a second patent for Conjugated Psilocin™ Once issued, this patent will provide additional coverage for psilocin mucate compositions VANCOUVER, British Columbia & STUART, Fla. / Nov 18, 2024 / Business Wire / Lobe Sciences, Ltd. ("Lobe Sciences" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”) , biopharmaceutical companies... Read More

VANCOUVER, British Columbia / Oct 16, 2024 / Business Wire / Lobe Sciences Ltd ("Lobe" or the "Company") (CSE: LOBE), (OTCQB: LOBEF) , a biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce the appointment of Enclave Capital and Peak Asset Management (the “Bankers”) to begin the process of raising funds to advance the development of the... Read More

U.S. Patent Office issues patent number 12,102,616 Patent covers the compositions of matter, methods of use and methods of production for Conjugated Psilocin™ Alera Pharma, Inc., (a newly established wholly owned subsidiary of Lobe Sciences), to proceed with fund-raising and clinical development of Conjugated Psilocin™ in neurological disorders VANCOUVER, British Columbia & STUART, Fla. / Oct 02, 2024 / Business Wire / Lobe... Read More

Alera Pharma, Inc. is a newly formed C-Corp wholly owned by Lobe Sciences, Ltd. Mr. Rick Goulburn is appointed as the Chief Executive Officer of Alera Pharma, Inc. Dr. Frederick D. Sancilio has been appointed as Chairman of the Alera Pharma, Inc. while Dr. Harry Jacobson, Mr. Wesley Ramjeet, and Mr. Goulburn are appointed as Members of the Board. Lobe Sciences Australia Pty Ltd. will become a subsidiary of Alera Pharma, Inc.... Read More

Annual General Meeting elects new Board of Directors: Dr. Frederick D. Sancilio, Dr. Harry Jacobson and Mr. Wesley Ramjeet Board announces resignations of CEO Philip Young and COO Baxter Phillips III The Board of Directors appoints Dr. Frederick D. Sancilio as Chairman and CEO of the company Mr. Rick Goulburn appointed to the Board as its fourth member Mr. Jeremy Wright joins the company as Board Advisor VANCOUVER, British... Read More

Company Exploring Alternative Value Creation Opportunities Convertible note for $500,000.00 USD, Short-term Debt Reduced and Balance Sheet Strengthened to Prepare the Company for Long Term Funding Strategy Annual General Meeting Set for 22 July 2024 VANCOUVER, British Columbia / Jun 04, 2024 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on... Read More

Accomplished Investor and Serial Entrepreneur VANCOUVER, British Columbia / Jun 03, 2024 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Wesley Ramjeet has agreed to join its Board of Directors in the coming months. With over two decades of experience as a... Read More

Providing a Proven Track Record of Driving Growth and Innovation VANCOUVER, British Columbia / May 31, 2024 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors. Dr. Sancilio brings over four decades... Read More

Physician, Fund Manager, Investor, Inventor Former Vice Chancellor at Vanderbilt University Medical Center Former Board Director For Renal Care Group and Kinetic Concepts VANCOUVER, British Columbia / May 30, 2024 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Dr.... Read More

VANCOUVER, British Columbia / May 21, 2024 / Business Wire / Lobe Sciences Ltd. (“Lobe” or the “Company”) (OTCQB: LOBEF) (CSE: LOBE), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases and Clearway Global, LLC (“Clearway”), a wholly owned subsidiary of Sancilio & Company (“Sancilio”), a pharmaceutical services company focused on value creation strategies, are pleased to announce... Read More

12-month data confirming that L-130 is the first reported stable oral psilocin First-in-Man clinical data demonstrates the superior PK profile of L-130 2023 sales of $1.1M (CAD) for Altemia ® VANCOUVER, British Columbia / Jan 08, 2024 / Business Wire / Lobe Sciences Ltd. ( OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases... Read More

Phase 1 results show significantly increased bioavailability for its stable psilocin compared to psilocybin L-130 Phase 2 Trial Planned for 2024 VANCOUVER, British Columbia / Dec 07, 2023 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead... Read More

L-130 passes 12 months ongoing stability VANCOUVER, British Columbia / Dec 05, 2023 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the Company’s lead clinical asset, L-130, a proprietary stabilized psilocin conjugate drug candidate, recently surpassed the 12-month... Read More

VANCOUVER, British Columbia / Sep 18, 2023 / Business Wire / Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced today that Mathew Lee will join the organization as Chief Financial Officer, effective September 18, 2023. “Appointing Mathew is part of our... Read More

VANCOUVER, British Columbia / Sep 14, 2023 / Business Wire / Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases announced that on August 30, 2023 it signed an amendment to the share purchase agreement to acquire a 100% interest in Altemia™ & Company, LLC (“ Seller ”)... Read More

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments and Commercial Inventory and Intellectual Property. Vancouver,... Read More

First-in-Man trial for Lobe’s proprietary stabilized psilocin analogue All subjects dosed with no significant adverse events to date VANCOUVER, British Columbia / Jun 27, 2023 / Business Wire / Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the initiation of a Phase 1, pharmacokinetic... Read More

Phillips also named President of Altemia & Co., a Lobe Sciences Company VANCOUVER, British Columbia / Jun 07, 2023 / Business Wire / Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced the appointment of Baxter Phillips III, MBA, to the newly created position of Chief Operating Officer (COO)... Read More

Distribution Agreement Grants Pentec Exclusive Distribution Rights for Altemia Lobe’s Novel Sickle Cell Anemia Medical Food VANCOUVER, British Columbia / May 17, 2023 / Business Wire / Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat orphan diseases today announced it has entered into a commercial distribution... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the " Company "), a North American Biopharmaceutical Company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today provides an update on its acquisition of the Vitamind Brand and intellectual property (" Vitamind ") pursuant to an asset purchase agreement... Read More

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and Generate Commercial Revenue in the Second Half of 2023 Acquisition also Includes an International License Agreement With Double Digit Royalty and Milestone Payments, Commercial Inventory and Intellectual Property. Vancouver,... Read More

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that Philip Young, CEO and Executive Chairman, will present at the SEQUIRE CANNABIS & PSYCHEDELICS CONFERENCE, April 5 th at 10:00AM... Read More

Dosing In Human Clinical Trial To Commence Within Weeks Vancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused medicines for Orphan and Rare diseases today announced that its exclusive commercial manufacturing partner has received their initial... Read More

Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe Sciences QCL agrees to supply Lobe Sciences research and commercial quantities of two new chemical entities, L-130 and L-131 under an exclusive arrangement Lobe Sciences Ltd. and QCL have entered into an agreement for the development of commercial formulations of L-130 for the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease today announced a financing in the amount of USD $250,000. This investment will be in the form of a convertible note (the... Read More

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today congratulated the people of Australia for the decision by the TGA (Therapeutic Goods Administration) to reschedule Psilocybin and MDMA... Read More

Dr. Lauren R. Natbony to be Principal Investigator Vancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient-focused psychedelic-derived medicines for neurologic and brain disease, today announced that it has signed an Investigator Initiated Research... Read More

Endorsement underscores transition into a fully integrated biotechnology company Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced its Board of Directors voted to receive... Read More

Vancouver, British Columbia--(Newsfile Corp. - January 18, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing patient focused psychedelic derived medicines for neurologic and brain disease today announced an updated overview for 2023. Mr. Philip Young, Chairman and Chief Executive Officer of the Company, stated,... Read More

Vancouver, British Columbia--(Newsfile Corp. - November 30, 2022) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced an update for its clinical development plans for its proprietary Psilocin based compound L-130. Philip J. Young, Chairman and... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has completed the synthesis of bulk L-130, a proprietary form of psilocin, and of the clinical supplies to be used in upcoming trials. The L-130 was manufactured in compliance with U.S. cGMPs... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that Baxter F. Phillips III has been appointed to the Board of Directors of the Company, effective October 3, 2022. Mr. Phillips has more than 20 years of experience leading multinational corporate... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced that it has expanded its patent portfolio through the filing of international patents in Canada, the United States, Europe and Australia for Methods, Compositions and Devices for Treating Mild... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has incorporated Lobe Sciences Australia Pty Ltd., a 100% owned Australian subsidiary of the Company, to facilitate the three or more clinical trials in Australia with newly announced partner... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease, today announced that it has closed a non-brokered private placement of units (the "Units") for gross proceeds of $1,347,500 (the "Offering"). "We are extremely pleased to close this financing and are thankful for... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into a term sheet contemplating convertible note financing bearing interest at 15% per annum with a term of 12 months (the "Convertible Notes") with Cantheon Capital ("Cantheon") for... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has updated its Corporate Slide Deck which among other initiatives, describes its plans for advancing the development of its psilocin analogues L-130 and L-131. Philip Young, CEO of Lobe Sciences... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds. Philip Young, CEO of Lobe Sciences stated, "Our patent portfolio now consists... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") announces that further to the Company's June 6, 2022, news release, the record date for the six for one consolidation has been adjusted to June 10, 2022. The Canadian Securities Exchange has published a bulletin confirming that trading will remain halted June 9, 2022, and resume trading on a consolidated basis on Friday, June 10. About Lobe Sciences Ltd.... Read More

Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) (" Lobe " or the " Company ") announces that its board of directors has authorized the implementation of a consolidation (the " Consolidation ") of the Company's common shares (the " Shares ") on the basis of one (1) post-Consolidation Share for every six (6) pre-Consolidation Shares, which will become effective on June 9, 2022 (the " Effective Date "). Neither the Company's... Read More